260 related articles for article (PubMed ID: 28407622)
1. Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
Oncology; 2017; 93(1):62-66. PubMed ID: 28407622
[TBL] [Abstract][Full Text] [Related]
2. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
[TBL] [Abstract][Full Text] [Related]
3. Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab.
Taniguchi Y; Tamiya A; Isa SI; Nakahama K; Okishio K; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Oct; 37(10):5857-5862. PubMed ID: 28982912
[TBL] [Abstract][Full Text] [Related]
4. Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
Iijima Y; Hirotsu Y; Amemiya K; Ooka Y; Mochizuki H; Oyama T; Nakagomi T; Uchida Y; Kobayashi Y; Tsutsui T; Kakizaki Y; Goto T; Miyashita Y; Omata M
Eur J Cancer; 2017 Nov; 86():349-357. PubMed ID: 29078173
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic Antigen as a Predictive Biomarker of Response to Nivolumab in Non-small Cell Lung Cancer.
Kataoka Y; Hirano K; Narabayashi T; Hara S; Fujimoto D; Tanaka T; Ebi N; Tomii K; Yoshioka H
Anticancer Res; 2018 Jan; 38(1):559-563. PubMed ID: 29277824
[TBL] [Abstract][Full Text] [Related]
6. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
Zhuo M; Chen H; Zhang T; Yang X; Zhong J; Wang Y; An T; Wu M; Wang Z; Huang J; Zhao J
Cancer Biomark; 2018; 22(3):467-476. PubMed ID: 29758930
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
8. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.
Turgeman I; Wollner M; Hassoun G; Bonstein L; Bar-Sela G
Anticancer Drugs; 2017 Aug; 28(7):811-814. PubMed ID: 28574922
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
Tanvetyanon T; Creelan BC; Antonia SJ
Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
[TBL] [Abstract][Full Text] [Related]
11. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer.
Parikh K; Kumar A; Ahmed J; Anwar A; Puccio C; Chun H; Fanucchi M; Lim SH
Cancer Immunol Immunother; 2018 Sep; 67(9):1365-1370. PubMed ID: 29968154
[TBL] [Abstract][Full Text] [Related]
12. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.
Kawakami H; Tanizaki J; Tanaka K; Haratani K; Hayashi H; Takeda M; Kamata K; Takenaka M; Kimura M; Chikugo T; Sato T; Kudo M; Ito A; Nakagawa K
Invest New Drugs; 2017 Aug; 35(4):529-536. PubMed ID: 28317087
[TBL] [Abstract][Full Text] [Related]
13. Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
Ricciuti B; Metro G; Baglivo S; Colabrese D; Chiari R; Bennati C; Paglialunga L
J Thorac Oncol; 2017 May; 12(5):e51-e55. PubMed ID: 28434516
[No Abstract] [Full Text] [Related]
14. The Association Between Chemotherapy Immediately Before Nivolumab and Outcomes Thereafter.
Nakahama K; Isa SI; Tamiya A; Taniguchi Y; Shiroyama T; Suzuki H; Inoue T; Tamiya M; Hirashima T; Imamura F; Atagi S
Anticancer Res; 2017 Oct; 37(10):5885-5891. PubMed ID: 28982916
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients.
Puszkiel A; Noé G; Boudou-Rouquette P; Cossec CL; Arrondeau J; Giraud JS; Thomas-Schoemann A; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2017 May; 139():30-36. PubMed ID: 28260630
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
17. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.
Leventakos K; Mansfield AS
BioDrugs; 2016 Oct; 30(5):397-405. PubMed ID: 27411930
[TBL] [Abstract][Full Text] [Related]
18. Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations.
Nakao M; Muramatsu H; Kagawa Y; Suzuki Y; Sakai Y; Kurokawa R; Fujita K; Sato H
Anticancer Res; 2017 Jul; 37(7):3781-3786. PubMed ID: 28668874
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Ulmeanu R; Antohe I; Anisie E; Antoniu S
Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
[TBL] [Abstract][Full Text] [Related]
20. Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.
Usui Y; Udagawa H; Matsumoto S; Imai K; Ohashi K; Ishibashi M; Kirita K; Umemura S; Yoh K; Niho S; Osame K; Goto K
J Thorac Oncol; 2017 May; 12(5):e41-e43. PubMed ID: 28017788
[No Abstract] [Full Text] [Related]
[Next] [New Search]
